Age related macular degeneration
Conditions
Interventions
Ranibizumab
Sponsors
Mie University Graduate School of Medicine Department of Ophthalmology
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: Subjects were eligible if the following criteria were met. 1) ability to provide written informed consent for this study 2) age>=50years old 3) intravitreal injection of ranibizumab as a first therapy for neovascular age-related macular degeneration (typical AMD and PCV) 4) best corrected visual acuity>=0.05
Exclusion criteria
Exclusion criteria: 1) past intravitreal anti-VEGF therapy in the study eye 2) past intravitreal or subtenon injection of steroid therapy in the study eye 3) past vitrectomy therapy in the study eye 4) infection or suspicion of infection in eyes or periocular region 5) severe intraocular inflammation in eyes 6) past allergic reaction for ranibizumab 7) past allergic reaction for fluorescein, indocyanine green or iodine 8) pregnancy (positive pregnancy test) or lactating women 9) other conditions that the investigator believed would pose a significant hazard to the subject if investigational therapy were initiated.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| The change of best corrected visual acuity and central retinal thickness (at 12th and 24th months). | — |
Secondary
| Measure | Time frame |
|---|---|
| 1:A drop-out rate of the third month and the twelfth month 2:The study continuance rate until 24 months | — |
Countries
Japan
Contacts
Public ContactHisashi Matsubara
Mie University Graduate School of Medicine Department of Ophthalmology
Outcome results
None listed